Festinavir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Festinavir
Festinavir skeletal.svg
Systematic (IUPAC) name
1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
Clinical data
Legal status Investigational
Identifiers
ATC code None
PubChem CID 3008897
ChemSpider 2278330
UNII 6IE83O6NGA YesY
ChEMBL CHEMBL124363
NIAID ChemDB 209894
Synonyms 4'-ethynylstavudine
Chemical data
Formula C12H12N2O4 
Mol. mass 248.235 g/mol

Festinavir is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. Festinavir is a nucleoside reverse transcriptase inhibitor that is active against HIV resistant to both abacavir and tenofovir, making the drug a candidate for people with multi-drug resistant (MDR) strains of the virus. Festinavir is a derivative of stavudine (d4T), but is less toxic.[citation needed] It was originally developed at Yale University.[1]

References[edit]

  1. ^ Alcorn, Keith (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.